Revenue view includes in-line products and royalty revenue from Evrysdi. Sees FY25 GAAP R&D and SG&A expense $805M-$835M; Non-GAAP R&D and SG&A expense $730M-$760 million, excluding estimated non-cash, stock-based compensation expense of $75M.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- Truist sees no read-throughs to PTC, Wave Life from uniQure news
- PTC Therapeutics price target raised to $77 from $63 at Jefferies
- PTCT Upcoming Earnings Report: What to Expect?
- PTC Therapeutics price target raised to $87 from $76 at BofA
- Optimistic Buy Rating for PTC Therapeutics Driven by Strong Demand and Promising Sales Projections for Sephience